Norwood, Massachusetts, United States · Hybrid
Description Corbus Pharmaceuticals is building its first in-house pharmacovigilance team to support a growing late-stage portfolio. The Drug Safety Associate I will serve as the primary ICSR case processor, managing end-…
Skills: Case Processing, Data Entry, MedDRA Coding, WHODrug Coding, ICSR Management
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The role involves end-to-end ICSR case processing, including triage, coding, and narrative authoring within Veeva Vault Safety. The associate is responsible for ensuring expedited regulatory submissions meet FDA, EMA, and ICH timelines.
Requires a Bachelor's degree in Pharmacy, Nursing, or Life Sciences with 3-4 years of experience in drug safety or clinical research. Proficiency in MedDRA and familiarity with ICH and FDA/EMA reporting requirements are essential.
Description
Corbus Pharmaceuticals is building its first in-house pharmacovigilance team to support a growing late-stage portfolio. The Drug Safety Associate I will serve as the primary ICSR case processor, managing end-to-end intake and data entry in Veeva Vault Safety and ensuring expedited regulatory submissions meet ICH E2B and FDA/EMA timelines. This is a hands-on operational role ideal for a new-to-industry scientist eager to build deep PV expertise in a high-growth biotech setting. This is a hybrid role to Norwood, Ma requiring 3 days on site and 2 days remote weekly.
Requirements
This is a foundational hire in a first-in-kind in-house PV team. The successful candidate will have direct visibility into regulatory strategy, aggregate reporting, and signal management — exposure that typically takes years to obtain at larger organisations. Competitive compensation, a collaborative science-driven culture, and a clear development pathway toward a Senior or Specialist role.
Corbus is a close-knit global team of high-achieving, innovative, creative and, above all else, passionate employees. We hire for personality as well as for skill. At Corbus, we take pride in our “family” atmosphere where each person’s contribution is vital to our success. As a Corbus employee, you are empowered to think creatively and be proactive in your approach. There is no place for politics or red tape here.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies in oncology and obesity. Our mission is to help people defeat serious illness by advancing differentiated scientific approaches targeting well-understood biological pathways with significant unmet medical need. Corbus’ lead oncology program, CRB-701, is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4-expressing tumors and is being developed for multiple solid tumor indications. Our obesity program, CRB-913, is a highly peripherally restricted CB1 receptor inverse agonist designed to support meaningful weight loss while minimizing central nervous system side effects. Together, these programs reflect our commitment to advancing transformative therapies through rigorous science and clinical innovation.
Headquartered in Norwood, Massachusetts, Corbus fosters a collaborative, entrepreneurial environment where employees are empowered to make meaningful contributions and help shape the future of the company. For more information, visit corbuspharma.com and connect with us on LinkedIn. Corbus Pharmaceuticals Holdings, Inc. is an equal opportunity employer.
Connecting innovation to purpose to improve the futures of cancer and obesity patients.
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity.
Offices: 500 River Ridge Dr, Norwood, Massachusetts 02062, US
Connecting innovation to purpose to improve the futures of cancer and obesity patients.
Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) is a clinical-stage company focused on oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity.
Offices: 500 River Ridge Dr, Norwood, Massachusetts 02062, US
